Astria Therapeutics: Hold Rating Amid Acquisition and Financial Stability with Future Growth Prospects

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Astria Therapeutics, with a price target of $13.00.

Sam Slutsky has given his Hold rating due to a combination of factors surrounding Astria Therapeutics. The acquisition by BioCryst Pharmaceuticals, expected to close in Q1 2026, values Astria’s stock at $13.00 per share, which includes both cash and stock components. This acquisition price is a key consideration, as it reflects the current market valuation and potential future growth tied to BioCryst’s strategic plans.
Additionally, Astria’s financial position, with $227.7 million in cash and investments, is projected to support operations into 2028. Despite this financial stability, the company’s recent net losses and the ongoing costs associated with its Phase 3 program are factors that temper enthusiasm. The anticipated milestones, such as the Phase 3 ALPHA-ORBIT results expected in early 2027, also play a role in maintaining a cautious outlook. Overall, these elements contribute to the decision to rate the stock as Hold, balancing potential growth with existing financial and operational challenges.

According to TipRanks, Slutsky is a 5-star analyst with an average return of 27.4% and a 48.77% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Astria Therapeutics, and Celldex.